48 completed, 8 terminated, 3 recruiting, 3 unknown. 23 Phase 1, 16 Phase 2, 15 Phase 3, 6 Phase 4, 2 Not applicable.
Follow Mannkind Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Nintedanib Dry Powder Inhalation, Placebo - Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Mannkind Corporation | 153 | 2026-05-15 | 2026-09-14 |
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes Technosphere Insulin, Basal insulin - Type 1 Diabetes Mellitus | Phase 2 | Recruiting | Mannkind Corporation | 100 | 2026-02-04 | 2026-08-13 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis MNKD-201(Nintedanib DPI), Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Completed | Mannkind Corporation | 27 | 2025-12-22 | 2026-07-22 |
| Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery Control IQ + sleep or exercise activity with TI - Diabetes Mellitus, Type 1 | Not applicable | Recruiting | Jaeb Center for Health Research | 30 | 2025-06-05 | 2026-07-16 |
| Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes Inhaled Technosphere Insulin - Diabetes, Gestational, Pregnancy Complications | Phase 2 / Phase 3 | Completed | Jaeb Center for Health Research | 30 | 2025-06-02 | 2026-10-19 |
| ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension Clofazimine Inhalation Suspension, Placebo - MAC Lung Disease, Treatment Refractory MAC Lung Disease | Phase 3 | Terminated | Mannkind Corporation | 132 | 2024-09-11 | 2025-11-12 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers (Part A) MKND-201, Placebo, (Part B) MKND-201 - Healthy Volunteers | Phase 1 | Unknown | Mannkind Corporation | 40 | 2024-05-28 | 2024-08-06 |
| INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Afrezza, insulin degludec, Rapid-acting Insulin Analog - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Mannkind Corporation | 141 | 2023-07-07 | 2024-08-09 |
| Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) - Type 1 Diabetes | Phase 4 | Completed | Mannkind Corporation | 33 | 2022-03-31 | 2025-04-08 |
| Afrezza® INHALE-1 Study in Pediatrics Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Mannkind Corporation | 319 | 2021-09-29 | 2025-05-06 |
| Afrezza® Dosing Optimization Study Afrezza Dose 1, Afrezza Dose 2 - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Mannkind Corporation | 20 | 2021-04-09 | 2023-09-18 |
| A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections Afrezza Inhalant Product - Type 2 Diabetes Treated With Insulin | Phase 4 | Unknown | Diabetes and Glandular Disease Clinic | 29 | 2019-02-27 | 2020-01-30 |
| Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers Treprostinil Inhalation Powder - Pulmonary Arterial Hypertension | Phase 1 | Completed | Mannkind Corporation | 36 | 2018-03-09 | 2018-10-30 |
| Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients Afrezza Inhalant Product - Type2 Diabetes | Phase 3 | Completed | Model Clinical Research LLC | 20 | 2017-10-16 | 2024-06-26 |
| A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone Afrezza plus One Drop | Premium, One Drop | Premium - Diabetes Mellitus, Type 2 | Phase 4 | Unknown | Informed Data Systems, Inc. | 400 | 2017-10-05 | 2019-02-26 |
| Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study Technosphere insulin - Diabetes Mellitus, Type 1 | Phase 4 | Completed | University of Colorado, Denver | 60 | 2017-09-30 | 2022-02-22 |
| Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Afrezza - Type 1 Diabetes Mellitus | Phase 2 | Completed | Mannkind Corporation | 30 | 2017-09-28 | 2021-04-06 |
| PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) Technosphere Insulin SAR439065 Afrezza® - Type 1 Diabetes Mellitus | Phase 1 | Completed | Mannkind Corporation | 22 | 2015-07-01 | 2017-03-15 |
| Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus SAR439065, Insulin lispro - Type 1 Diabetes Mellitus | Phase 1 | Completed | Mannkind Corporation | 30 | 2015-06-01 | 2017-04-13 |
| Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers TI-Inhalation Powder A, TI-Inhalation Powder B - Healthy Volunteers | Phase 1 | Completed | Mannkind Corporation | 38 | 2013-11-01 | 2014-10-02 |
Showing 20 of 64. Sign in to see all of them.
Diabetes Mellitus, Type 2 (24) · Diabetes Mellitus, Type 1 (23) · Diabetes Mellitus (11) · Insulin Resistance (8) · Melanoma (5) · Respiratory Aspiration (4) · Asthma (3) · Idiopathic Pulmonary Fibrosis (2) · Respiratory Tract Infections (2) · Actinomycetales Infections (1) · Anus Neoplasms (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Biliary Tract Neoplasms (1) · Bone Neoplasms (1)
Insulin (12) · Insulin Aspart (4) · Insulin Lispro (4) · Insulin Glargine (3) · insulin degludec (3) · Albuterol (2) · Insulin, Short-Acting (2) · 3,6-bis(N-fumaryl-N(n-butyl)amino)-2,5-diketopiperazine (1) · Fluticasone (1) · Injections, Subcutaneous (1) · Insulin Detemir (1) · Metformin (1) · Methacholine Chloride (1) · Moxifloxacin (1) · Secretagogues (1)
United States (49) · Russia (11) · Brazil (8) · Canada (8) · United Kingdom (7) · Ukraine (6) · Germany (5) · Poland (5) · Spain (5) · Argentina (4) · Czechia (4) · Mexico (4) · Chile (3) · Netherlands (3) · Australia (1)
Anders Boss (3) · Kevin Kaiserman, MD (3) · Anders Boss, MD (2) · Anders H. Boss (2) · Robert Baughman, PhD (2) · Amy Valent, DO (1) · Anders Boss, MD, MPH (1) · Barbara Hickingbottom, JD, MD (1) · Chandra Osborn, PhD, MPH (1) · Irl B. Hirsch, MD (1)
PMID 12833467, PMID 18678610, PMID 20609970, PMID 21999640, PMID 26180109, PMID 26253730, PMID 30207748, PMID 31811662, PMID 34773608, PMID 36652106, PMID 40531276, PMID 42377397
2015 (2)